Cargando…
Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations
Although it has always been believed that radiation has immunosuppressive effects, more and more preclinical and clinical trials have shown that the combination of radiotherapy and immunotherapy has a potential synergistic effect to treat cancers including urological malignancies. When radiotherapy...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917304/ https://www.ncbi.nlm.nih.gov/pubmed/33658847 http://dx.doi.org/10.2147/CMAR.S288337 |
_version_ | 1783657670437240832 |
---|---|
author | Lei, Haoran Shi, Ming Xu, Hang Bai, Shengjiang Xiong, Xingyu Wei, Qiang Yang, Lu |
author_facet | Lei, Haoran Shi, Ming Xu, Hang Bai, Shengjiang Xiong, Xingyu Wei, Qiang Yang, Lu |
author_sort | Lei, Haoran |
collection | PubMed |
description | Although it has always been believed that radiation has immunosuppressive effects, more and more preclinical and clinical trials have shown that the combination of radiotherapy and immunotherapy has a potential synergistic effect to treat cancers including urological malignancies. When radiotherapy is combined with immunotherapy, improved prognosis has been observed in different urinary tumors. However, there is no standard treatment, such as the optimal dose/fractionation and the sequence of immunotherapy and radiotherapy. In this review, we discussed the effects of radiotherapy on the cancer immune system and emphasized the synergy of radiotherapy combined with immunotherapy. Although it has significantly improved the prognosis of tumors, there are still some unresolved questions about how to best use this combination in clinical practice. Ongoing trials will provide further information on the interaction of radiotherapy combined with immunotherapy, and are expected to guide clinical practice and improve clinical outcomes. |
format | Online Article Text |
id | pubmed-7917304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-79173042021-03-02 Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations Lei, Haoran Shi, Ming Xu, Hang Bai, Shengjiang Xiong, Xingyu Wei, Qiang Yang, Lu Cancer Manag Res Review Although it has always been believed that radiation has immunosuppressive effects, more and more preclinical and clinical trials have shown that the combination of radiotherapy and immunotherapy has a potential synergistic effect to treat cancers including urological malignancies. When radiotherapy is combined with immunotherapy, improved prognosis has been observed in different urinary tumors. However, there is no standard treatment, such as the optimal dose/fractionation and the sequence of immunotherapy and radiotherapy. In this review, we discussed the effects of radiotherapy on the cancer immune system and emphasized the synergy of radiotherapy combined with immunotherapy. Although it has significantly improved the prognosis of tumors, there are still some unresolved questions about how to best use this combination in clinical practice. Ongoing trials will provide further information on the interaction of radiotherapy combined with immunotherapy, and are expected to guide clinical practice and improve clinical outcomes. Dove 2021-02-24 /pmc/articles/PMC7917304/ /pubmed/33658847 http://dx.doi.org/10.2147/CMAR.S288337 Text en © 2021 Lei et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Lei, Haoran Shi, Ming Xu, Hang Bai, Shengjiang Xiong, Xingyu Wei, Qiang Yang, Lu Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations |
title | Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations |
title_full | Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations |
title_fullStr | Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations |
title_full_unstemmed | Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations |
title_short | Combined Treatment of Radiotherapy and Immunotherapy for Urological Malignancies: Current Evidence and Clinical Considerations |
title_sort | combined treatment of radiotherapy and immunotherapy for urological malignancies: current evidence and clinical considerations |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917304/ https://www.ncbi.nlm.nih.gov/pubmed/33658847 http://dx.doi.org/10.2147/CMAR.S288337 |
work_keys_str_mv | AT leihaoran combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations AT shiming combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations AT xuhang combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations AT baishengjiang combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations AT xiongxingyu combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations AT weiqiang combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations AT yanglu combinedtreatmentofradiotherapyandimmunotherapyforurologicalmalignanciescurrentevidenceandclinicalconsiderations |